All In Biotech

Drug Trial Radar · NCT05004311

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

An Open-label, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cenerimod After Single-dose Administration in Subjects With Severe Renal Impairment and Control Subjects

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Sep 27, 2021

Primary completion

Jul 27, 2023

Study completion Aug 10, 2023

Sponsor

Lead sponsor
Viatris Innovation GmbHIndustry
Sponsor type
Industry
First posted
Aug 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate the PK of cenerimod in participants with severe renal impairment as compared to healthy control participants.

Conditions

  • Healthy
  • Renal Impairment

Interventions

  • CenerimodDrug

    A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve (AUC) from time zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of cenerimodTime frame: Total duration: up to 52 days
  2. Area under the plasma concentration-time curve (AUC from 0 to infinity) of cenerimodTime frame: Total duration: up to 52 days
  3. The maximum plasma concentration (Cmax) of cenerimodTime frame: Total duration: up to 52 days
  4. The time to reach Cmax (tmax) of cenerimodTime frame: Total duration: up to 52 days
  5. Terminal half-life (t½) of cenerimodTime frame: Total duration: up to 52 days
  6. Apparent oral clearance (CL/F) of cenerimodTime frame: Total duration: up to 52 days
  7. Extent of cenerimod protein plasma binding (PPB)Time frame: Total duration: up to 52 days
  8. Apparent volume of distribution (Vz/F) of cenerimodTime frame: Total duration: up to 52 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • BlueClinical Phase 1 Hospital de Prelado

    Porto, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.